Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

BACKGROUND: Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cancer and lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karzai, Fatima, VanderWeele, David, Madan, Ravi A., Owens, Helen, Cordes, Lisa M., Hankin, Amy, Couvillon, Anna, Nichols, Erin, Bilusic, Marijo, Beshiri, Michael L., Kelly, Kathleen, Krishnasamy, Venkatesh, Lee, Sunmin, Lee, Min-Jung, Yuno, Akira, Trepel, Jane B., Merino, Maria J., Dittamore, Ryan, Marté, Jennifer, Donahue, Renee N., Schlom, Jeffrey, Killian, Keith J., Meltzer, Paul S., Steinberg, Seth M., Gulley, James L., Lee, Jung-Min, Dahut, William L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280368/
https://www.ncbi.nlm.nih.gov/pubmed/30514390
http://dx.doi.org/10.1186/s40425-018-0463-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280368/
https://www.ncbi.nlm.nih.gov/pubmed/30514390
http://dx.doi.org/10.1186/s40425-018-0463-2

Ejemplares similares